<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypouricemia: Causes and clinical significance</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypouricemia: Causes and clinical significance</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypouricemia: Causes and clinical significance</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David B Mount, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard H Sterns, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypouricemia is arbitrarily defined as a serum urate concentration of less than 2 mg/dL (119 micromol/L). It occurs in approximately 2 percent of hospitalized patients and less than 0.5 percent of the normal population [<a href="#rid1">1</a>]. Hypouricemia may be caused by decreased uric acid production, uric acid oxidation due to treatment with uricase, or decreased renal tubular reabsorption due to inherited or acquired disorders [<a href="#rid2">2</a>]. There are no known abnormalities of intestinal uricolysis that produce hypouricemia. (See  <a class="medical medical_review" href="/d/html/1670.html" rel="external">"Urate balance"</a>.)</p><p>Hypouricemia has been thought of as a biochemical disorder with no clinical significance other than as a marker of underlying disease [<a href="#rid3">3</a>]. However, individuals with renal tubular urate wasting may have an increased incidence of acute kidney injury (AKI; previously called acute renal failure). (See  <a class="medical medical_review" href="/d/html/7238.html" rel="external">"Definition and staging criteria of acute kidney injury in adults"</a>.)</p><p class="headingAnchor" id="H3188296"><span class="h1">DECREASED PRODUCTION</span><span class="headingEndMark"> — </span>Decreased uric acid production can be caused by several rare inherited disorders of purine synthesis and catabolism and, more commonly, by acquired deficiency of xanthine oxidase due to <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> therapy or liver disease.</p><p class="headingAnchor" id="H3187616"><span class="h2">Inherited disorders</span><span class="headingEndMark"> — </span>Inherited disorders resulting in decreased uric acid production include hereditary xanthinuria and purine nucleosidase phosphorylase deficiency:</p><p class="bulletIndent1"><span class="glyph">●</span>Hereditary xanthinuria – Xanthine oxidase catalyzes the conversion of hypoxanthine to xanthine and of xanthine to uric acid. Deficiency of xanthine oxidase, which is inherited as an autosomal recessive trait, results in hereditary xanthinuria [<a href="#rid4">4,5</a>]. Striking hypouricemia is seen with levels usually below 1 mg/dL (59.5 micromol/L). Increased urinary excretion of relatively insoluble xanthine leads to the development of xanthine stones in approximately one-third of patients. Xanthine stones are managed with fluids to increase the urine output (which reduces the urine xanthine concentration) and with alkali administration (which modestly increases xanthine solubility) [<a href="#rid6">6</a>]. In a smaller number of patients, deposition of xanthine crystals in skeletal muscle produces myopathic symptoms.</p><p></p><p class="bulletIndent1">The diagnosis is suspected by the finding of hypouricemia, reduced urinary uric acid excretion, and increased xanthine excretion; it is confirmed by liver or intestinal biopsy with measurement of enzyme activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Purine nucleoside phosphorylase deficiency – Purine nucleoside phosphorylase (PNP) catalyzes the reaction in which inosine, deoxyinosine, and deoxyguanosine undergo phosphorylation to purine bases. PNP deficiency results in hypouricemia, developmental retardation, defective cellular immunity with lymphopenia, deceased T cells, and recurrent infections. (See  <a class="medical medical_review" href="/d/html/3943.html" rel="external">"Purine nucleoside phosphorylase deficiency"</a>.)</p><p></p><p class="headingAnchor" id="H3188304"><span class="h2">Acquired disorders</span><span class="headingEndMark"> — </span>Acquired deficiency of xanthine oxidase is considerably more common than inherited disorders of decreased production. The major acquired causes of xanthine oxidase deficiency are drugs (eg, <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>) and severe liver disease:</p><p class="bulletIndent1"><span class="glyph">●</span>Xanthine oxidase inhibitors – <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">Allopurinol</a> and <a class="drug drug_general" data-topicid="9079" href="/d/drug information/9079.html" rel="external">febuxostat</a> reduce the formation of uric acid by inhibiting xanthine oxidase activity and lowering intracellular phosphoribosyl pyrophosphate levels. This is the most common cause of hypouricemia, although it is unusual for the uric acid level to fall below 2.5 mg/dL (149 micromol/L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Liver disease – With severe hepatocellular injury, there may be sufficient loss of hepatic xanthine oxidase activity to produce hypouricemia. A renal tubular defect in urate reabsorption may also contribute [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H13090614"><span class="h1">URIC ACID OXIDATION</span><span class="headingEndMark"> — </span>Unlike most animal species, humans lack urate oxidase (uricase). Thus, in humans, uric acid is an end product of metabolism. Derivatives of uricase (<a class="drug drug_general" data-topicid="10189" href="/d/drug information/10189.html" rel="external">rasburicase</a>), which catalyzes the oxidation of uric acid to allantoin, are widely used in the prevention and treatment of acute kidney injury (AKI) in tumor lysis syndrome. A "PEGylated" rasburicase may be used in the management of refractory gout [<a href="#rid8">8</a>], causing profound hypouricemia.</p><p class="headingAnchor" id="H3188312"><span class="h1">INCREASED URINARY EXCRETION</span><span class="headingEndMark"> — </span>Increased urinary excretion of uric acid can be seen with familial hypouricemia (an inherited disorder) and in a variety of acquired conditions.</p><p class="headingAnchor" id="H9"><span class="h2">Familial renal hypouricemia</span><span class="headingEndMark"> — </span>Familial hypouricemia, which is caused by a defect in renal tubular urate transport, is a rare syndrome transmitted as an autosomal trait [<a href="#rid9">9-20</a>]. The defect appears to be more common in non-Ashkenazi Jews and Japanese individuals. In a report of 3258 Japanese outpatients, for example, renal hyperuricosuria and persistent hypouricemia were found in 4 (0.12 percent) [<a href="#rid11">11</a>]. The mechanism for hyperuricosuria has been studied using the anti-uricosuric agent <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> and the uricosuric drugs benzbromarone and <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a>. Most patients exhibit attenuated responses to both pyrazinamide and uricosurics, while a minority have an attenuated response to uricosurics but a preserved anti-uricosuric response to pyrazinamide [<a href="#rid20">20</a>]. The basic aspects of renal urate handling are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1670.html" rel="external">"Urate balance", section on 'Urinary excretion'</a>.)</p><p>The underlying defect in the great majority of patients is a mutation in a gene called <em>SLC22A12</em> that encodes for a renal urate-anion exchanger named uric acid transporter 1(URAT1) [<a href="#rid21">21,22</a>]. URAT1 is expressed in the luminal membrane of the proximal tubular cells and is responsible for a large portion of proximal urate reabsorption (<a class="graphic graphic_figure graphicRef83926" href="/d/graphic/83926.html" rel="external">figure 1</a>). The residual apical uptake of urate is likely mediated by the OAT10 (<em>SLC22A13</em>) urate-anion exchanger [<a href="#rid23">23</a>], in addition to GLUT9a (see below).</p><p>Familial renal hypouricemia has also been described in patients with mutations in the <em>SLC2A9</em> gene, which encodes a high-capacity urate transporter called GLUT9. Two GLUT9 variants include the GLUT9a and GLUT9b forms [<a href="#rid24">24-26</a>]. Urate reabsorption from the tubular lumen into the cell is mediated by URAT1 and OAT10, as mentioned above. Uric acid efflux from the cell across the basolateral membrane appears to be mediated solely by basolateral GLUT9a (<a class="graphic graphic_figure graphicRef83926" href="/d/graphic/83926.html" rel="external">figure 1</a>) [<a href="#rid27">27</a>]; the basolateral urate exchangers OAT1 and OAT3 function as the basolateral entry site for urate secretion [<a href="#rid28">28</a>], with no evident role in urate absorption across the proximal tubule (<a class="graphic graphic_figure graphicRef83925" href="/d/graphic/83925.html" rel="external">figure 2</a>).</p><p>The severity of the hypouricemia varies with the genetic defect:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients homozygous for URAT1 mutations typically have serum urate concentrations below 1.0 mg/dL (59.5 micromol/L) and a partial uric acid reabsorption defect with fractional excretion of urate that ranges between 40 and 90 percent. The uricosuric effect of benzbromarone and <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> is abolished in these patients, as is the anti-uricosuric effect of <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> [<a href="#rid22">22</a>] (see  <a class="medical medical_review" href="/d/html/1670.html" rel="external">"Urate balance", section on 'Urinary excretion'</a>). Clinical abnormalities are unusual, although nephrolithiasis is three to four times more common than in the general population, and a few cases of exercise-induced acute kidney injury (AKI) have been described [<a href="#rid29">29</a>]. (See <a class="local">'Acute kidney injury'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss-of-function mutations in GLUT9 cause more severe hypouricemia (close to zero) in homozygous individuals and are associated with a high incidence of renal calculi and exercise-induced AKI. In contrast to patients with mutations in URAT1, the loss of function of GLUT9 precludes uric acid reabsorption by all of the apical transporters (including URAT1) due to complete inhibition of basolateral uric acid efflux from the cell. The net effect is a fractional urate excretion of 100 to 150 percent; values above 100 percent reflect urate secretion. Urate secretion is mediated by a separate set of apical and basolateral urate transporters (<a class="graphic graphic_figure graphicRef83925" href="/d/graphic/83925.html" rel="external">figure 2</a>) (see  <a class="medical medical_review" href="/d/html/1670.html" rel="external">"Urate balance", section on 'Urinary excretion'</a>). The anti-uricosuric effect of <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> is retained in these patients [<a href="#rid25">25</a>], unlike those with URAT1 deficiency. Patients heterozygous for a GLUT9 loss-of-function mutation have moderately reduced serum uric acid levels. (See <a class="local">'Complications'</a> below.)</p><p></p><p class="headingAnchor" id="H3188323"><span class="h2">Acquired disorders</span><span class="headingEndMark"> — </span>Hypouricemia due to increased urinary excretion of uric acid results from a variety of conditions, as outlined below.</p><p class="headingAnchor" id="H10"><span class="h3">Fanconi syndrome</span><span class="headingEndMark"> — </span>Uric acid reabsorption in the proximal tubule can be decreased in the Fanconi syndrome, along with defects in the reabsorption of phosphate, glucose, and amino acids [<a href="#rid30">30</a>]. This syndrome has multiple causes, including cystinosis, multiple myeloma, and various drugs [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/6139.html" rel="external">"Cystinosis"</a> and  <a class="medical medical_review" href="/d/html/7210.html" rel="external">"Kidney disease in multiple myeloma and other monoclonal gammopathies: Etiology and evaluation"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Volume expansion</span><span class="headingEndMark"> — </span>Expansion of the extracellular fluid volume can be associated with hypouricemia by decreasing proximal tubular reabsorption of urate [<a href="#rid31">31</a>]. This is most commonly seen in patients receiving large volumes of intravenous fluids and in patients with primary polydipsia or the syndrome of inappropriate antidiuretic hormone (SIADH) [<a href="#rid32">32-35</a>]. (See  <a class="medical medical_review" href="/d/html/2354.html" rel="external">"Diagnostic evaluation of adults with hyponatremia"</a>.)</p><p>Hypouricemia can develop in patients receiving large volumes of intravenous fluids because the reabsorption of urate by the proximal tubule parallels that of sodium [<a href="#rid36">36</a>]. Restriction of sodium intake reduces both sodium and urate excretion and can produce hyperuricemia; by contrast, excess sodium intake (as with large volumes of intravenous fluids) increases both sodium and urate excretion and can produce hypouricemia [<a href="#rid37">37-40</a>]. Several short-term studies have shown that serum urate on a high-sodium diet (170 to 260 mmol/day) was 1.0 to 2.0 mg/dL lower than on a low-sodium diet (20 to 50 mmol/day) [<a href="#rid37">37-40</a>].</p><p>Water restriction resolves both the hyponatremia and hypouricemia in the SIADH, suggesting a primary role for volume expansion [<a href="#rid33">33</a>]. Both the vasopressin 2 (V2) and vasopressin 1 (V1) receptors may be important in the hypouricemia associated with SIADH:</p><p class="bulletIndent1"><span class="glyph">●</span>Activation of the V2 receptor by either natively produced vasopressin or <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> (a vasopressin analog that only stimulates the V2 receptor) leads to sodium absorption by the principal cells of the connecting tubule and cortical collecting duct [<a href="#rid41">41-43</a>]. The ensuing sodium retention reduces the reabsorption of sodium by the proximal tubule. As just discussed, the reduction in proximal sodium reabsorption is associated with a similar reduction in proximal urate reabsorption, which can produce hypouricemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, stimulation of the V1 receptor may also contribute to the uric acid wasting via an uncertain mechanism. The importance of this receptor is suggested by the observation that the induction of hyponatremia by the administration of <a class="drug drug_general" data-topicid="9330" href="/d/drug information/9330.html" rel="external">desmopressin</a> produces a significantly smaller fall in the serum uric acid concentration (29 versus 53 percent) than seen in patients with a similar degree of hyponatremia due to the SIADH (in which the native hormone stimulates both the V1 and V2 receptors) [<a href="#rid44">44</a>]. Consistent with this hypothesis, lack of V1 receptor activity in patients with central diabetes insipidus has been associated with hyperuricemia that is not improved with desmopressin therapy [<a href="#rid45">45</a>].</p><p></p><p>Hypouricemia may also occur in a substantial number of patients with thiazide-induced hyponatremia, in whom SIADH-like physiology is the evident cause of hyponatremia [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/2288.html" rel="external">"Diuretic-induced hyponatremia"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Intracranial disease</span><span class="headingEndMark"> — </span>Hypouricemia due to increased urate clearance has been described in patients with intracranial disease. One study, for example, evaluated 29 consecutive neurosurgical patients: 18 had an elevated fractional excretion of urate, and 7 had hypouricemia [<a href="#rid47">47</a>]. In some patients, the hypouricemia is associated with renal sodium wasting and hyponatremia, a disorder that has been called cerebral salt-wasting [<a href="#rid2">2,35,48</a>]. In contrast to the hypouricemia seen in the SIADH, the hypouricemia in cerebral salt-wasting should not be corrected by water restriction, because the primary problem appears to be a humoral substance released from the brain rather than volume expansion [<a href="#rid45">45</a>]. Alternatively, the apparent salt-wasting and increased urate clearance may reflect volume expansion due to <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, which is commonly administered to neurosurgical patients [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/2367.html" rel="external">"Cerebral salt wasting"</a> and  <a class="medical medical_review" href="/d/html/2354.html" rel="external">"Diagnostic evaluation of adults with hyponatremia"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Acquired immunodeficiency syndrome</span><span class="headingEndMark"> — </span>Increased fractional excretion of urate and hypouricemia may be seen in patients with acquired immunodeficiency syndrome (AIDS) [<a href="#rid50">50-52</a>]. In a study of 96 patients, for example, hypouricemia was found in 21 (22 percent) and was associated with cerebral atrophy in 12 who underwent cranial computed tomography (CT) [<a href="#rid50">50</a>]. Risk factors for hypouricemia in these and other patients include disseminated disease, central nervous system infection, and high-dose therapy with <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid50">50-52</a>]. The development of hypouricemia may be a poor prognostic factor [<a href="#rid50">50,51</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Drugs</span><span class="headingEndMark"> — </span>A number of drugs interfere with net renal tubular urate reabsorption and lower serum uric acid levels (<a class="graphic graphic_table graphicRef64646" href="/d/graphic/64646.html" rel="external">table 1</a>). Primary uricosurics such as <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> and benzbromarone inhibit multiple urate transporters, whereas <a class="drug_supplemental_data drug_dxy_dosage_form" data-topicid="106042" href="/contents/null?topicRef=2315&amp;source=see_link">lesinurad</a> is reportedly specific for OAT4 and URAT1 [<a href="#rid53">53,54</a>]. The most common other drugs with "off-target" uricosuria are high-dose <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> and high-dose salicylate therapy [<a href="#rid52">52,55,56</a>]. <a class="drug drug_general" data-topicid="91482" href="/d/drug information/91482.html" rel="external">Fenofibrate</a> also inhibits URAT1 with a uricosuric and hypouricemic effect [<a href="#rid57">57</a>]. In most instances, the serum uric acid concentration does not fall below normal levels. </p><p>The uricosuric action of the angiotensin II receptor blocker (ARB) <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> has been used to treat the hyperuricemia associated with <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> in heart transplant recipients; this effect appears to be more pronounced than that seen with an angiotensin-converting enzyme (ACE) inhibitor [<a href="#rid58">58</a>]. The uricosuria appears to occur via the inhibition of both URAT1 [<a href="#rid59">59</a>] and organic anion transporter 10 (OAT10) [<a href="#rid60">60</a>], the function of which is described above. (See <a class="local">'Familial renal hypouricemia'</a> above.)</p><p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have a uricosuric effect, likely through the inhibitory effect of glycosuria on urate reabsorption rather than direct transporter inhibition [<a href="#rid61">61</a>]. Clinically, SGLT2 inhibitors reduce serum uric acid and appear to reduce the risk of gout [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H11797806"><span class="h3">Inflammation</span><span class="headingEndMark"> — </span>Inflammatory cytokines appear to reduce net renal tubular reabsorption of urate, leading to hypouricemia. Urate levels are typically lower in the context of acute gout flares [<a href="#rid63">63</a>] due to an increase in urate excretion that has been linked to increases in cytokines and other inflammatory stimuli [<a href="#rid64">64</a>]. More severe renal hypouricemia has been described in sepsis. As an example, 16 out of 43 Taiwanese patients with severe acute respiratory syndrome (SARS) were shown to develop marked renal hypouricemia (mean serum uric acid, 1.7 mg/dL [100 micromol/L]), in association with elevated interleukin-8 levels [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Other</span><span class="headingEndMark"> — </span>Several other causes have been associated with hypouricemia due to increased urate excretion:</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy [<a href="#rid66">66</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Total <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a> [<a href="#rid67">67</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Malignancies, including Hodgkin lymphoma [<a href="#rid68">68-70</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus [<a href="#rid71">71,72</a>]; it is likely that decreased urate reabsorption is a function of glucosuria in these patients</p><p class="bulletIndent1"><span class="glyph">●</span>Amanita phalloides poisoning [<a href="#rid73">73</a>]</p><p></p><p class="headingAnchor" id="H16"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Although most patients with hypouricemia of any cause are asymptomatic, three complications related to renal hypouricemia can occur: acute kidney injury (AKI), nephrolithiasis, and reversible posterior leukoencephalopathy syndrome (also called posterior reversible encephalopathy syndrome, or PRES).</p><p class="headingAnchor" id="H17"><span class="h2">Acute kidney injury</span><span class="headingEndMark"> — </span>An increased incidence of AKI, often following exercise, has been described in patients with familial renal hypouricemia [<a href="#rid22">22,74-78</a>]. The largest reported experience comes from a review of 54 patients with renal hypouricemia, approximately 90 percent of whom were male [<a href="#rid74">74</a>]. Episodes of AKI most often occurred after strenuous exercise, such as a short-distance race. The initial symptoms were severe loin or abdominal pain and nausea, which usually developed within 6 to 12 hours after exercise. At presentation to medical care, the mean serum creatinine was 5.5 mg/dL (486 mmol/L), and the mean serum uric acid concentration was normal (4.4 mg/dL [262 micromol/L]), which was felt to be at least in part due to the kidney failure. After recovery, the serum uric acid fell to 0.7 mg/dL (42 micromol/L). Recovery of kidney function occurred in all patients, although some required hemodialysis. At follow-up, 13 patients (24 percent) developed recurrent AKI. In some patients, repeated episodes of AKI may lead to chronic kidney disease [<a href="#rid74">74</a>].</p><p>Data are limited on the frequency of AKI following exercise in patients with renal hypouricemia. The increase in relative risk was assessed in a study of 13 patients presenting with AKI following exercise, three of whom (23 percent) had renal hypouricemia [<a href="#rid75">75</a>]. This rate exceeded the expected incidence of familial renal hypouricemia by 200-fold. (See <a class="local">'Familial renal hypouricemia'</a> above.)</p><p>Two major pathogenetic mechanisms have been proposed for exercise-associated AKI in renal hypouricemia:</p><p class="bulletIndent1"><span class="glyph">●</span>Oxidative stress from reactive oxygen species generated during exercise, leading to renal vasoconstriction, ischemia, oxidant injury [<a href="#rid79">79</a>], and acute tubular injury (also called acute tubular necrosis, or ATN).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased uric acid production, leading to increased uric acid excretion and precipitation in the tubules, as occurs in tumor lysis syndrome and other causes of acute and marked tissue breakdown. (See  <a class="medical medical_review" href="/d/html/1154.html" rel="external">"Tumor lysis syndrome: Pathogenesis, clinical manifestations, definition, etiology and risk factors", section on 'Pathogenesis'</a> and  <a class="medical medical_review" href="/d/html/7379.html" rel="external">"Uric acid kidney diseases", section on 'Acute uric acid nephropathy'</a>.)</p><p></p><p>The majority of reported kidney biopsies in exercise-associated AKI in renal hypouricemia have demonstrated ATN without intratubular uric acid precipitation [<a href="#rid74">74,80</a>]. It is hypothesized that the reduction in circulating uric acid, which is a known antioxidant [<a href="#rid81">81</a>], impairs the ability of the kidney to cope with the increase in oxidative stress associated with strenuous exercise [<a href="#rid82">82</a>]. In a patient with renal hypouricemia and exercise-associated AKI, for example, both an acute increase in reactive oxygen species and a decreased antioxidant potential capacity were demonstrated soon after the initiation of exercise [<a href="#rid83">83</a>]. Consequently, many patients with a history of exercise-associated AKI are treated with oral <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a> and <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> in an attempt to increase serum antioxidant capacity [<a href="#rid74">74</a>].</p><p>Prolonged or intense exercise is also associated with an elevation in uric acid production, most likely due to muscle adenosine triphosphate (ATP) utilization. The subsequent rise in adenosine diphosphate (ADP) leads to an increase in the production of hypoxanthine, which is then converted to uric acid in the liver, leading to increases in serum uric acid and uric acid excretion [<a href="#rid84">84,85</a>]. Volume depletion during exercise can lead to a reduction in urine volume, which might promote uric acid precipitation in the tubules. Uric acid precipitation in the tubules can also occur with other causes of an acute increase in uric acid excretion, including high-dose <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [<a href="#rid52">52</a>].</p><p>The theory of uric acid precipitation is supported by the kidney biopsy demonstration of renal tubular obstruction by uric acid crystals in a single case report of exercise-induced AKI [<a href="#rid86">86</a>] and by an increased prevalence of uric acid nephrolithiasis in patients with renal hypouricemia. (See <a class="local">'Uric acid stone formation'</a> below.)</p><p>Further evidence comes from two patients with recurrent exercise-induced AKI that could be prevented by <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> therapy [<a href="#rid77">77,87</a>]. As an example, a Pakistani patient with recurrent exercise-induced AKI and four normals were studied with and without allopurinol during a physical fitness test [<a href="#rid77">77</a>]. Uric acid excretion without allopurinol increased from 0.46 mg/min at baseline to 1.49 mg/min at four hours after exercise, and the patient developed AKI. Uric acid excretion in controls was also 0.46 mg/min at baseline but only increased to 0.59 mg/min at four hours after exercise. After five days of allopurinol, the patient underwent the same fitness test without experiencing an increase in urate excretion or AKI. However, allopurinol is also an antioxidant, which could have explained the protection against AKI [<a href="#rid79">79</a>].</p><p>Through potentially similar mechanisms (ie, uric acid precipitation), the potent URAT1/OAT4 inhibitor <a class="drug_supplemental_data drug_dxy_dosage_form" data-topicid="106042" href="/contents/null?topicRef=2315&amp;source=see_link">lesinurad</a> has been reported to produce AKI in clinical trials [<a href="#rid23">23</a>]. In the Combining Lesinurad With <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">Allopurinol</a> in Inadequate Responders (CLEAR1) trial in patients with gout [<a href="#rid88">88</a>], creatinine elevations that were &gt;1.5 times baseline occurred in 1.0 percent of those on allopurinol alone, in 6 percent of patients on lesinurad 200 mg/day plus allopurinol, and in 16 percent of those on lesinurad 400 mg/day plus allopurinol. Similar rates of renal adverse events were reported in two other trials of lesinurad [<a href="#rid89">89,90</a>]. The use of lesinurad in patients with gout is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"</a>.)</p><p class="headingAnchor" id="H559528"><span class="h2">Uric acid stone formation</span><span class="headingEndMark"> — </span>Patients with renal hypouricemia are at increased risk for nephrolithiasis [<a href="#rid15">15-18,24,91</a>]. In two series of 19 patients with familial renal hypouricemia, 5 (26 percent) had a history of kidney stones [<a href="#rid24">24,91</a>]. Most of these reports described uric acid stones and successful treatment with urinary alkalinization [<a href="#rid15">15-18</a>]. However, hyperuricosuria may predispose to calcium oxalate stones [<a href="#rid92">92</a>], which have also been described in patients with renal hypouricemia [<a href="#rid93">93,94</a>]. (See <a class="local">'Familial renal hypouricemia'</a> above and  <a class="medical medical_review" href="/d/html/7378.html" rel="external">"Kidney stones in adults: Uric acid nephrolithiasis", section on 'Treatment'</a>.)</p><p>Patients with renal hypouricemia have increased fractional excretion of urate but, in theory, should have normal 24-hour urinary excretion since urate production (which is unchanged in renal hypouricemia) and urate excretion are roughly equal in the steady state. Thus, an increased risk of uric acid stones would seem counterintuitive. However, many patients with familial renal hypouricemia have moderate or marked hyperuricosuria, possibly due to diversion of urate elimination from the intestine to the urine (ie, less gastrointestinal clearance of the daily uric acid load in favor of more urinary clearance) [<a href="#rid20">20</a>]. How this might occur is not known. In addition, some of these patients have hypercalciuria via an uncertain mechanism, which is another risk factor for stone formation [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H546377344"><span class="h2">Reversible posterior leukoencephalopathy syndrome (PRES)</span><span class="headingEndMark"> — </span>Reversible posterior leukoencephalopathy syndrome (also called posterior reversible encephalopathy syndrome, or PRES) was described in two patients with exercise-associated AKI due to renal hypouricemia, one with loss-of-function mutations in <em>SLC22A12</em>/<em>URAT</em>1 [<a href="#rid95">95</a>], and the other with loss-of-function mutations in <em>SLC2A9</em>/<em>GLUT9</em> [<a href="#rid96">96</a>]. One of these patients had recurrent episodes of PRES that occurred in absence of hypertension. The pathophysiology underlying the association of hypouricemia and PRES is unclear. (See  <a class="medical medical_review" href="/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p class="headingAnchor" id="H4204186452"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109733.html" rel="external">"Society guideline links: Fluid and electrolyte disorders in adults"</a>.)</p><p class="headingAnchor" id="H10360291"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hypouricemia is arbitrarily defined as a serum urate concentration of less than 2 mg/dL (119 micromol/L). It is a fairly uncommon disorder, occurring in approximately 2 percent of hospitalized patients and less than 0.5 percent of the normal population. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypouricemia can be caused by decreased uric acid production, uric acid oxidation due to treatment with uricase, or enhanced urate excretion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased uric acid production can be due to rare inherited disorders of purine synthesis and catabolism (hereditary xanthinuria or xanthine oxidase deficiency) or, more commonly, acquired deficiency of xanthine oxidase (as with <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a> or severe liver disease). (See <a class="local">'Decreased production'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased urinary uric acid excretion may be seen in the following disorders and with certain drugs (see <a class="local">'Increased urinary excretion'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Familial renal hypouricemia, due to mutations in URAT1 or GLUT9, which encode for proteins responsible for urate reabsorption in the proximal tubule (see <a class="local">'Familial renal hypouricemia'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fanconi syndrome, in which uric acid reabsorption in the proximal tubule is decreased, along with reductions in the reabsorption of one or more of the following: phosphate, glucose, potassium, bicarbonate, and amino acids (see <a class="local">'Fanconi syndrome'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Expansion of the extracellular fluid volume, most commonly seen in patients receiving large volumes of intravenous fluids, those with primary polydipsia, and in the syndrome of inappropriate antidiuretic hormone secretion (SIADH) (see <a class="local">'Volume expansion'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intracranial disease in association with renal sodium wasting and hyponatremia (cerebral salt-wasting). (See <a class="local">'Intracranial disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acquired immunodeficiency syndrome (AIDS), which may be related to intracranial disease and tends to correlate with disseminated disease and a poor prognosis (see <a class="local">'Acquired immunodeficiency syndrome'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drugs, such as high-dose <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, high-dose salicylate, <a class="drug_supplemental_data drug_dxy_dosage_form" data-topicid="106042" href="/contents/null?topicRef=2315&amp;source=see_link">lesinurad</a>, and <a class="drug drug_general" data-topicid="9574" href="/d/drug information/9574.html" rel="external">losartan</a> (<a class="graphic graphic_table graphicRef64646" href="/d/graphic/64646.html" rel="external">table 1</a>) (see <a class="local">'Drugs'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three complications related to renal hypouricemia can occur: acute kidney injury (AKI), nephrolithiasis, and posterior reversible leukoencephalopathy syndrome (also called posterior reversible encephalopathy syndrome, or PRES). (See <a class="local">'Complications'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ogino K, Hisatome I, Saitoh M, et al. Clinical significance of hypouricemia in hospitalized patients. J Med 1991; 22:76.</a></li><li><a class="nounderline abstract_t">Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998; 32:917.</a></li><li><a class="nounderline abstract_t">Ramsdell CM, Kelley WN. The clinical significance of hypouricemia. Ann Intern Med 1973; 78:239.</a></li><li class="breakAll">Holmes EW, Wyngaarden JB. Hereditary xanthinuria. In: The Metabolic Basis of Inherited Disease, 6th ed, Scriver C, Beaudet AL, Sly WS, et al (Eds), McGraw-Hill, New York 1989.</li><li><a class="nounderline abstract_t">Levartovsky D, Lagziel A, Sperling O, et al. XDH gene mutation is the underlying cause of classical xanthinuria: a second report. Kidney Int 2000; 57:2215.</a></li><li><a class="nounderline abstract_t">Seegmiller JE. Xanthine stone formation. Am J Med 1968; 45:780.</a></li><li><a class="nounderline abstract_t">Michelis MF, Warms PC, Fusco RD, Davis BB. Hypouricemia and hyperuricosuria in Laennec cirrhosis. Arch Intern Med 1974; 134:681.</a></li><li><a class="nounderline abstract_t">Sundy JS, Becker MA, Baraf HS, et al. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 2008; 58:2882.</a></li><li><a class="nounderline abstract_t">Greene ML, Marcus R, Aurbach GD, et al. Hypouricemia due to isolated renal tubular defect. Dalmatian dog mutation in man. Am J Med 1972; 53:361.</a></li><li><a class="nounderline abstract_t">Khachadurian AK, Arslanian MJ. Hypouricemia due to renal uricosuria. A case study. Ann Intern Med 1973; 78:547.</a></li><li><a class="nounderline abstract_t">Hisatome I, Ogino K, Kotake H, et al. Cause of persistent hypouricemia in outpatients. Nephron 1989; 51:13.</a></li><li><a class="nounderline abstract_t">Barajas de Frutos D, Bravo Mancheño B, Palomino Urda N, Pedrero Vera J. Familial hypouricaemia due to an isolated tubular defect of urate reabsorption. Pediatr Nephrol 1993; 7:83.</a></li><li><a class="nounderline abstract_t">Hisatome I, Kato T, Miyakoda H, et al. Renal hypouricemia with both drug-insensitive secretion and defective reabsorption of urate: a novel type of renal hypouricemia. Nephron 1993; 64:447.</a></li><li><a class="nounderline abstract_t">Shichiri M, Iwamoto H, Shiigai T. Hypouricemia due to increased tubular urate secretion. Nephron 1987; 45:31.</a></li><li><a class="nounderline abstract_t">Frank M, Many M, Sperling O. Familial renal hypouricaemia: two additional cases with uric acid lithiasis. Br J Urol 1979; 51:88.</a></li><li><a class="nounderline abstract_t">Hedley JM, Phillips PJ. Familial hypouricaemia associated with renal tubular uricosuria and uric acid calculi: case report. J Clin Pathol 1980; 33:971.</a></li><li><a class="nounderline abstract_t">Gofrit O, Verstandig AG, Pode D. Bilateral obstructing ureteral uric acid stones in an infant with hereditary renal hypouricemia. J Urol 1993; 149:1506.</a></li><li><a class="nounderline abstract_t">Hisatome I, Tanaka Y, Kotake H, et al. Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate. Nephron 1993; 65:578.</a></li><li><a class="nounderline abstract_t">Iwai N, Mino Y, Hosoyamada M, et al. A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese. Kidney Int 2004; 66:935.</a></li><li><a class="nounderline abstract_t">Sperling O. Hereditary renal hypouricemia. Mol Genet Metab 2006; 89:14.</a></li><li><a class="nounderline abstract_t">Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417:447.</a></li><li><a class="nounderline abstract_t">Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15:164.</a></li><li><a class="nounderline abstract_t">Mandal AK, Mercado A, Foster A, et al. Uricosuric targets of tranilast. Pharmacol Res Perspect 2017; 5:e00291.</a></li><li><a class="nounderline abstract_t">Dinour D, Gray NK, Campbell S, et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010; 21:64.</a></li><li><a class="nounderline abstract_t">Matsuo H, Chiba T, Nagamori S, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008; 83:744.</a></li><li><a class="nounderline abstract_t">Caulfield MJ, Munroe PB, O'Neill D, et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med 2008; 5:e197.</a></li><li><a class="nounderline abstract_t">Kimura T, Takahashi M, Yan K, Sakurai H. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells. PLoS One 2014; 9:e84996.</a></li><li><a class="nounderline abstract_t">Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008; 33:180.</a></li><li><a class="nounderline abstract_t">Uribarri J, Oh MS. Renal hypouricemia and absorptive hypercalciuria: a real syndrome. Nephron 1993; 63:172.</a></li><li><a class="nounderline abstract_t">Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 2003; 41:292.</a></li><li><a class="nounderline abstract_t">Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest 1975; 55:283.</a></li><li><a class="nounderline abstract_t">Peretz A, Decaux G, Famaey JP. Hypouricemia and intravenous infusions. J Rheumatol 1983; 10:66.</a></li><li><a class="nounderline abstract_t">Beck LH. Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1979; 301:528.</a></li><li><a class="nounderline abstract_t">Decaux G, Schlesser M, Coffernils M, et al. Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia. Clin Nephrol 1994; 42:102.</a></li><li><a class="nounderline abstract_t">Decaux G, Prospect F, Namias B, Soupart A. Utility of serum uric acid determination in the differential diagnosis between central diabetes insipidus and primary polydipsia (abstract). J Am Soc Nephrol 1996; 7:1348.</a></li><li><a class="nounderline abstract_t">Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993; 270:354.</a></li><li><a class="nounderline abstract_t">Egan BM, Lackland DT. Biochemical and metabolic effects of very-low-salt diets. Am J Med Sci 2000; 320:233.</a></li><li><a class="nounderline abstract_t">Masugi F, Ogihara T, Hashizume K, et al. Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J Hum Hypertens 1988; 1:293.</a></li><li><a class="nounderline abstract_t">Del Río A, Rodríguez-Villamil JL. Metabolic effects of strict salt restriction in essential hypertensive patients. J Intern Med 1993; 233:409.</a></li><li><a class="nounderline abstract_t">Ruppert M, Diehl J, Kolloch R, et al. Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults. Klin Wochenschr 1991; 69 Suppl 25:51.</a></li><li><a class="nounderline abstract_t">Ecelbarger CA, Kim GH, Terris J, et al. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol 2000; 279:F46.</a></li><li><a class="nounderline abstract_t">Bugaj V, Pochynyuk O, Stockand JD. Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption. Am J Physiol Renal Physiol 2009; 297:F1411.</a></li><li><a class="nounderline abstract_t">Bankir L, Fernandes S, Bardoux P, et al. Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol 2005; 16:1920.</a></li><li><a class="nounderline abstract_t">Decaux G, Namias B, Gulbis B, Soupart A. Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol 1996; 7:805.</a></li><li><a class="nounderline abstract_t">Decaux G, Prospert F, Namias B, Soupart A. Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia. Am J Med 1997; 103:376.</a></li><li><a class="nounderline abstract_t">Liamis G, Christidis D, Alexandridis G, et al. Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia. J Investig Med 2007; 55:36.</a></li><li><a class="nounderline abstract_t">Maesaka JK, Venkatesan J, Piccione JM, et al. Abnormal urate transport in patients with intracranial disease. Am J Kidney Dis 1992; 19:10.</a></li><li><a class="nounderline abstract_t">Maesaka JK, Batuman V, Yudd M, et al. Hyponatremia and hypouricemia: differentiation from SIADH. Clin Nephrol 1990; 33:174.</a></li><li><a class="nounderline abstract_t">Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol 2008; 19:194.</a></li><li><a class="nounderline abstract_t">Maesaka JK, Cusano AJ, Thies HL, et al. Hypouricemia in acquired immunodeficiency syndrome. Am J Kidney Dis 1990; 15:252.</a></li><li><a class="nounderline abstract_t">Collazos J, Blanco MS, Guerra E, et al. Sequential evaluation of serum urate concentrations in AIDS patients with infections of the central nervous system. Clin Chem Lab Med 2000; 38:1293.</a></li><li><a class="nounderline abstract_t">Chertow GM, Seifter JL, Christiansen CL, O'Donnell WJ. Trimethoprim-sulfamethoxazole and hypouricemia. Clin Nephrol 1996; 46:193.</a></li><li><a class="nounderline abstract_t">Perez-Ruiz F, Sundy JS, Miner JN, et al. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis 2016; 75:1074.</a></li><li><a class="nounderline abstract_t">Fleischmann R, Kerr B, Yeh LT, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford) 2014; 53:2167.</a></li><li><a class="nounderline abstract_t">YU TF, GUTMAN AB. Paradoxical retention of uric acid by uricosuric drugs in low dosage. Proc Soc Exp Biol Med 1955; 90:542.</a></li><li><a class="nounderline abstract_t">Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 1959; 38:1298.</a></li><li><a class="nounderline abstract_t">Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med 2010; 49:89.</a></li><li><a class="nounderline abstract_t">Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66:268.</a></li><li><a class="nounderline abstract_t">Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens 2008; 21:1157.</a></li><li><a class="nounderline abstract_t">Toyoda Y, Kawamura Y, Nakayama A, et al. OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts. Front Pharmacol 2022; 13:842717.</a></li><li><a class="nounderline abstract_t">Suijk DLS, van Baar MJB, van Bommel EJM, et al. SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function. Clin J Am Soc Nephrol 2022; 17:663.</a></li><li><a class="nounderline abstract_t">Fralick M, Chen SK, Patorno E, Kim SC. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med 2020; 172:186.</a></li><li><a class="nounderline abstract_t">Ayvazian JH, Ayvazian IF. Changes in serum and urinary uric acid with the development of symptomatic gout. J Clin Invest 1963; 42:1835.</a></li><li><a class="nounderline abstract_t">Urano W, Yamanaka H, Tsutani H, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol 2002; 29:1950.</a></li><li><a class="nounderline abstract_t">Wu VC, Huang JW, Hsueh PR, et al. Renal hypouricemia is an ominous sign in patients with severe acute respiratory syndrome. Am J Kidney Dis 2005; 45:88.</a></li><li><a class="nounderline abstract_t">Lind T, Godfrey KA, Otun H, Philips PR. Changes in serum uric acid concentrations during normal pregnancy. Br J Obstet Gynaecol 1984; 91:128.</a></li><li><a class="nounderline abstract_t">Derus CL, Levinson DJ, Bowman B, et al. Altered fractional excretion of uric acid during total parenteral nutrition. J Rheumatol 1987; 14:978.</a></li><li><a class="nounderline abstract_t">Cooper DS. Oat-cell carcinoma and severe hypouricemia. N Engl J Med 1973; 288:321.</a></li><li><a class="nounderline abstract_t">Magoula I, Tsapas G, Kountouras J, Paletas K. Cholangiocarcinoma and severe renal hypouricemia: a study of the renal mechanisms. Am J Kidney Dis 1991; 18:514.</a></li><li><a class="nounderline abstract_t">Bennett JS, Bond J, Singer I, Gottlieb AJ. Hypouricemia in Hodgkin's disease. Ann Intern Med 1972; 76:751.</a></li><li><a class="nounderline abstract_t">Shichiri M, Iwamoto H, Shiigai T. Diabetic renal hypouricemia. Arch Intern Med 1987; 147:225.</a></li><li><a class="nounderline abstract_t">Magoula I, Tsapas G, Paletas K, Mavromatidis K. Insulin-dependent diabetes and renal hypouricemia. Nephron 1991; 59:21.</a></li><li><a class="nounderline abstract_t">Zawadzki J, Jankowska I, Moszczyńska A, Januszewicz P. Hypouricemia due to increased tubular secretion of urate in children with Amanita phalloides poisoning. Nephron 1993; 65:375.</a></li><li><a class="nounderline abstract_t">Ohta T, Sakano T, Igarashi T, et al. Exercise-induced acute renal failure associated with renal hypouricaemia: results of a questionnaire-based survey in Japan. Nephrol Dial Transplant 2004; 19:1447.</a></li><li><a class="nounderline abstract_t">Ishikawa I, Sakurai Y, Masuzaki S, et al. Exercise-induced acute renal failure in 3 patients with renal hypouricemia. Nihon Jinzo Gakkai Shi 1990; 32:923.</a></li><li><a class="nounderline abstract_t">Murakami T, Kawakami H, Fukuda M, Furukawa S. Patients with renal hypouricemia are prone to develop acute renal failure--why? Clin Nephrol 1995; 43:207.</a></li><li><a class="nounderline abstract_t">Yeun JY, Hasbargen JA. Renal hypouricemia: prevention of exercise-induced acute renal failure and a review of the literature. Am J Kidney Dis 1995; 25:937.</a></li><li><a class="nounderline abstract_t">Mima A, Ichida K, Matsubara T, et al. Acute renal failure after exercise in a Japanese sumo wrestler with renal hypouricemia. Am J Med Sci 2008; 336:512.</a></li><li><a class="nounderline abstract_t">Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984; 74:1156.</a></li><li><a class="nounderline abstract_t">Ohta T, Sakano T, Ogawa T, et al. Exercise-induced acute renal failure with renal hypouricemia: a case report and a review of the literature. Clin Nephrol 2002; 58:313.</a></li><li><a class="nounderline abstract_t">Peden DB, Hohman R, Brown ME, et al. Uric acid is a major antioxidant in human nasal airway secretions. Proc Natl Acad Sci U S A 1990; 87:7638.</a></li><li><a class="nounderline abstract_t">Vollaard NB, Shearman JP, Cooper CE. Exercise-induced oxidative stress:myths, realities and physiological relevance. Sports Med 2005; 35:1045.</a></li><li><a class="nounderline abstract_t">Kaneko K, Taniguchi N, Tanabe Y, et al. Oxidative imbalance in idiopathic renal hypouricemia. Pediatr Nephrol 2009; 24:869.</a></li><li><a class="nounderline abstract_t">Sahlin K, Ekberg K, Cizinsky S. Changes in plasma hypoxanthine and free radical markers during exercise in man. Acta Physiol Scand 1991; 142:275.</a></li><li><a class="nounderline abstract_t">Hellsten-Westing Y, Kaijser L, Ekblom B, Sjödin B. Exchange of purines in human liver and skeletal muscle with short-term exhaustive exercise. Am J Physiol 1994; 266:R81.</a></li><li><a class="nounderline abstract_t">Erley CM, Hirschberg RR, Hoefer W, Schaefer K. Acute renal failure due to uric acid nephropathy in a patient with renal hypouricemia. Klin Wochenschr 1989; 67:308.</a></li><li><a class="nounderline abstract_t">Bhasin B, Stiburkova B, De Castro-Pretelt M, et al. Hereditary renal hypouricemia: a new role for allopurinol? Am J Med 2014; 127:e3.</a></li><li><a class="nounderline abstract_t">Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study). Arthritis Rheumatol 2017; 69:203.</a></li><li><a class="nounderline abstract_t">Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 2017; 76:811.</a></li><li><a class="nounderline abstract_t">Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. Arthritis Rheumatol 2017; 69:1903.</a></li><li><a class="nounderline abstract_t">Dinour D, Bahn A, Ganon L, et al. URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews. Nephrol Dial Transplant 2011; 26:2175.</a></li><li><a class="nounderline abstract_t">Sorensen CM, Chandhoke PS. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31:915.</a></li><li><a class="nounderline abstract_t">Kaneko K, Yamanobe T, Onoda M, et al. Analysis of urinary calculi obtained from a patient with idiopathic hypouricemia using micro area x-ray diffractometry and LC-MS. Urol Res 2005; 33:415.</a></li><li><a class="nounderline abstract_t">Nishizaki N, Fujinaga S, Hirano D, et al. Hereditary renal hypouricemia: a cause of calcium oxalate urolithiasis in a young female. Clin Nephrol 2012; 77:161.</a></li><li><a class="nounderline abstract_t">Fujinaga S, Ito A, Nakagawa M, et al. Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1. Eur J Pediatr 2013; 172:1557.</a></li><li><a class="nounderline abstract_t">Shima Y, Nozu K, Nozu Y, et al. Recurrent EIARF and PRES with severe renal hypouricemia by compound heterozygous SLC2A9 mutation. Pediatrics 2011; 127:e1621.</a></li></ol></div><div id="topicVersionRevision">Topic 2315 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1895016" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical significance of hypouricemia in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856507" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Regulation of renal urate excretion: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4683752" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The clinical significance of hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4683752" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The clinical significance of hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844591" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : XDH gene mutation is the underlying cause of classical xanthinuria: a second report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4879836" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Xanthine stone formation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4413749" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypouricemia and hyperuricosuria in Laennec cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759308" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5054729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypouricemia due to isolated renal tubular defect. Dalmatian dog mutation in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4694039" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hypouricemia due to renal uricosuria. A case study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2915747" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cause of persistent hypouricemia in outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8439489" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Familial hypouricaemia due to an isolated tubular defect of urate reabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8341392" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Renal hypouricemia with both drug-insensitive secretion and defective reabsorption of urate: a novel type of renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3808146" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hypouricemia due to increased tubular urate secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/465979" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Familial renal hypouricaemia: two additional cases with uric acid lithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7430362" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Familial hypouricaemia associated with renal tubular uricosuria and uric acid calculi: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8501797" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Bilateral obstructing ureteral uric acid stones in an infant with hereditary renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8302413" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15327384" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16678460" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hereditary renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12024214" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Molecular identification of a renal urate anion exchanger that regulates blood urate levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694169" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28357121" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Uricosuric targets of tranilast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926891" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Homozygous SLC2A9 mutations cause severe renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19026395" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18842065" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : SLC2A9 is a high-capacity urate transporter in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24409316" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270321" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multiple organic anion transporters contribute to net renal excretion of uric acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8450908" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Renal hypouricemia and absorptive hypercalciuria: a real syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12552490" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Drug-induced Fanconi's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1127100" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The influence of the extracellular fluid volume on the tubular reabsorption of uric acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6842488" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypouricemia and intravenous infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/460306" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hypouricemia in the syndrome of inappropriate secretion of antidiuretic hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7955571" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Utility of serum uric acid determination in the differential diagnosis between central diabetes insipidus and primary polydipsia (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315780" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Uric acid metabolism and tubular sodium handling. Results from a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11061347" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biochemical and metabolic effects of very-low-salt diets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3221377" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Changes in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487006" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Metabolic effects of strict salt restriction in essential hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1921253" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt-resistant normotensive adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894786" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19692483" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Activation of the epithelial Na+ channel in the collecting duct by vasopressin contributes to water reabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888562" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8738818" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9375705" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hyperuricemia as a clue for central diabetes insipidus (lack of V1 effect) in the differential diagnosis of polydipsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17441410" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1739076" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Abnormal urate transport in patients with intracranial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2350904" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hyponatremia and hypouricemia: differentiation from SIADH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216309" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cerebral salt wasting versus SIADH: what difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2305765" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hypouricemia in acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11205696" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Sequential evaluation of serum urate concentrations in AIDS patients with infections of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8879855" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trimethoprim-sulfamethoxazole and hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26742777" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24509406" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13273509" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Paradoxical retention of uric acid by uricosuric drugs in low dosage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13673086" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20075570" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of fenofibrate on uric acid metabolism and urate transporter 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9701277" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670416" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35462902" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : OAT10/SLC22A13 Acts as a Renal Urate Re-Absorber: Clinico-Genetic and Functional Analyses With Pharmacological Impacts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35322793" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931526" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14083171" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Changes in serum and urinary uric acid with the development of symptomatic gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12233891" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696447" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Renal hypouricemia is an ominous sign in patients with severe acute respiratory syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6696858" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Changes in serum uric acid concentrations during normal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3123676" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Altered fractional excretion of uric acid during total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4345447" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Oat-cell carcinoma and severe hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1656732" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cholangiocarcinoma and severe renal hypouricemia: a study of the renal mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5025326" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypouricemia in Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3813739" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Diabetic renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944743" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Insulin-dependent diabetes and renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8289987" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hypouricemia due to increased tubular secretion of urate in children with Amanita phalloides poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150354" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Exercise-induced acute renal failure associated with renal hypouricaemia: results of a questionnaire-based survey in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2250410" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Exercise-induced acute renal failure in 3 patients with renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7774083" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Patients with renal hypouricemia are prone to develop acute renal failure--why?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7771493" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Renal hypouricemia: prevention of exercise-induced acute renal failure and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092327" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Acute renal failure after exercise in a Japanese sumo wrestler with renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6434591" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Oxygen free radicals in ischemic acute renal failure in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12400848" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Exercise-induced acute renal failure with renal hypouricemia: a case report and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2217195" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Uric acid is a major antioxidant in human nasal airway secretions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336008" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Exercise-induced oxidative stress:myths, realities and physiological relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18936980" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Oxidative imbalance in idiopathic renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1877376" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Changes in plasma hypoxanthine and free radical markers during exercise in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8304559" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Exchange of purines in human liver and skeletal muscle with short-term exhaustive exercise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2709741" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Acute renal failure due to uric acid nephropathy in a patient with renal hypouricemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262806" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hereditary renal hypouricemia: a new role for allopurinol?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27564409" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821644" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28597604" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21148271" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12474638" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Hyperuricosuric calcium nephrolithiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16133578" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Analysis of urinary calculi obtained from a patient with idiopathic hypouricemia using micro area x-ray diffractometry and LC-MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22257548" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Hereditary renal hypouricemia: a cause of calcium oxalate urolithiasis in a young female.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23525542" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21536615" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Recurrent EIARF and PRES with severe renal hypouricemia by compound heterozygous SLC2A9 mutation.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
